In summary, these findings raise concern that activation of FXR may alter the cholesterol metabolism in a way that increases the susceptibility to atherosclerosis and thus limit its application in patients with NAFLD. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.